Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Non-inferiority Trial of Dapaconazole Versus Ketoconazole

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03320486
Recruitment Status : Recruiting
First Posted : October 25, 2017
Last Update Posted : January 16, 2019
Sponsor:
Information provided by (Responsible Party):
Biolab Sanus Farmaceutica

Brief Summary:
The main purpose of this study is to demonstrate that dapaconazole cream 2% (experimental drug) is non-inferior to ketoconazole cream 2% (Nizoral® - active comparator) for the treatment of dermatological lesions of Tinea pedis, when applied to the skin (topically) once daily during 28 days. Additionally, the safety and tolerability aspects will be evaluated in a descriptive way, through the observation of the incidence of adverse events.

Condition or disease Intervention/treatment Phase
Tinea Pedis Drug: Dapaconazole Drug: Ketoconazole Phase 3

Detailed Description:

This is a non-inferiority, phase 3, multicenter, double-blind, randomized (allocation of treatment), balanced, controlled (active comparator) trial, with two parallel groups in a 1:1 proportion.

Randomization will depend on inclusion/exclusion criteria, taking into account the confirmation of diagnosis by the direct mycological test performed during the screening phase. However, cases whose diagnosis is not additionally confirmed by positive fungal culture (sampled during the screening phase) will be excluded from the efficacy analysis.

Participants will show up to the clinic, for treatment, during 42 consecutive days, when one of the investigational products (according to the randomization) will be applied by a blind member of the study staff. A non-blind member of the study staff will weigh the corresponding investigational product and pass on to the blind member only a spatula with the weighed product, in order to maintain the blinded aspect of the trial.

For exploratory purposes, clinical and mycological evaluations will also be performed after 7 and after 14 days of treatment.

Safety analysis will be performed considering all the randomized patients to which at least one dose of the investigational products has been applied, regardless of the result of the fungal culture.

Conclusion of non-inferiority will be based on the per protocol set. It will be deemed as per protocol those participants who do not miss more than 20% of the applications and, also, no more than four consecutive application days.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 360 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 3, Multicenter, Double-blind, Randomized, Non-inferiority Clinical Trial of Dapaconazole Cream 2% (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral®, Janssen-Cilag Farmacêutica Ltda.) in Patients With Tinea Pedis
Actual Study Start Date : November 1, 2017
Estimated Primary Completion Date : November 2019
Estimated Study Completion Date : November 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group 1 - dapaconazole cream 2%
Topical application of dapaconazole cream 2%, once daily, during 42 days.
Drug: Dapaconazole
Application of 1 to 3 grams, depending on the lesion extension, per affected foot.
Other Name: Zilt

Active Comparator: Group 2 - ketoconazole cream 2%
Topical application of ketoconazole cream 2%, once daily, during 42 days.
Drug: Ketoconazole
Application of 1 to 3 grams, depending on the lesion extension, per affected foot.
Other Name: Nizoral®




Primary Outcome Measures :
  1. Proportion of participants with therapeutic cure [ Time Frame: 28 days of treatment ]

    Proportion of participants, in each treatment group, who achieved therapeutic cure, defined as both clinical cure and mycological cure, on the assessment performed after 28 days of treatment.

    Clinical cure is defined as a score ≤ 2 for the sum of scores attributed to each sign or symptom (erythema, maceration/peeling, fissuring/cracking, itching and burning) as evaluated by a four-point categorical scale (0=absent, 1=mild, 2=moderate, 3=severe).

    Mycological cure is defined as negative result for the direct mycological examination (potassium hydroxide [KOH] test) and a negative fungal culture.



Secondary Outcome Measures :
  1. Proportion of participants with therapeutic cure [ Time Frame: 42 days of treatment ]
    Proportion of participants, in each treatment group, who achieved therapeutic cure, on the assessment performed after 42 days of treatment.

  2. Proportion of participants maintaining therapeutic cure [ Time Frame: 14 (±3) days after the end of treatment ]
    Proportion of participants, in each treatment group, maintaining the therapeutic cure in the evaluation performed approximately 14 days after the end of the 42 days treatment period.

  3. Proportion of participants maintaining therapeutic cure [ Time Frame: 28 (±5) days after the end of treatment ]
    Proportion of participants, in each treatment group, maintaining the therapeutic cure in the evaluation performed approximately 28 days after the end of the 42 days treatment period.

  4. Number of days until clinical cure [ Time Frame: up to 42 days ]
    Number of days elapsed between the day of start of treatment and the day when the clinical cure is diagnosed, according to the daily assessment, in each treatment group.

  5. Number of adverse events per participant [ Time Frame: up to 80 (±5) days ]
    Number of adverse events, in each treatment group, including clinically relevant alterations of vital signs and laboratory tests.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants aged from 18 to 65 years old, male, or female with no childbearing potential or who are using an effective contraceptive method and who do not plan to become pregnant during the study period.
  • Presence of dermatological lesion(s) of Tinea pedis, with a global clinical severity score ≥ 4, being a minimum score of 2 for itching or desquamation/maceration and a minimum score of 2 for erythema, having, also, the diagnosis confirmed by direct mycological (KOH) test.
  • No previous treatment with antimycotic medication, in the last 2 months, for the current dermatologic lesion.
  • No evidence of other significant diseases, that, at the investigator's discretion, may affect the participation in the clinical trial, in accordance with the protocol requirements.
  • Ability to understand the nature and the objective of the clinical trial, including the risks and possible side effects; intention to cooperate with the investigator and act in accordance with the protocol requirements, as confirmed by the informed consent form signature.

Exclusion Criteria:

  • Existing hepatic and/or renal diseases or other pathologic findings, which might interfere with the safety and tolerability of the active ingredients.
  • Screening laboratory tests presenting deviations deemed as clinically significant, which, due to possible risks, prevents the participation in clinical trial.
  • Known hypersensitivity to ketoconazole or to chemically related compounds (azoles) or to the compounds of the investigational products.
  • Participants with severe or multiple drugs allergies, unless judged by the investigator as not clinically relevant to the participation in the clinical trial.
  • Positive anti human immunodeficiency virus (anti-HIV) test, positive Hepatitis B Surface Antigen (HBs-Ag) test or positive anti hepatitis C virus (anti-HCV) test.
  • Treatment, within 3 months prior to the start of the clinical trial treatment, with any drug known to have a well-established toxic potential to major organs.
  • Pregnant or lactating women
  • Participation in any clinical trial, or intake of any investigational product, within the last twelve months prior to the inclusion in the clinical trial.
  • Presence of onychomycosis.
  • Presence of "Moccasin type" Tinea pedis.
  • Presence of infected Tinea pedis, or any other infection or pathology that may confuse the treatment evaluation.
  • History of drug addiction.
  • Diseases that may alter the immune system and, consequently, the host's response to the fungal presence (immunosuppressed participants), as well as the use of systemic immunosuppressive drugs, chemotherapy or radiotherapy, during the 3 months prior to the start of treatment.
  • Use of drugs that may interfere with the assessment of the results, as well as use of topical immunosuppressants, topical antibiotics or topical corticosteroids, within 2 months prior to the start of treatment.
  • Use of antipruriginous drugs, including antihistaminics, within 72 hours prior to the start of treatment.
  • History of alcohol dependence and/or regular intake of alcoholic food or beverages containing ≥ 20 g of pure ethanol per day.
  • Any prior treatment for the present lesion which, at investigator discretion, may interfere with the objectives of the clinical trial.
  • Participants who might be non-compliant to the study treatment and/or to the requirements and procedures of the protocol.
  • Participants who are unable to understand written and verbal instructions, in particular those regarding the risks and inconveniences to which they will be exposed during the participation in the clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03320486


Contacts
Layout table for location contacts
Contact: Gilberto De Nucci, MD +55 19 9 9178-8879 denucci@gilbertodenucci.com

Locations
Layout table for location information
Brazil
Galeno Desenvolvimento de Pesquisas Clinicas Ltda. - ME Recruiting
Campinas, SP, Brazil
Sponsors and Collaborators
Biolab Sanus Farmaceutica
Investigators
Layout table for investigator information
Principal Investigator: Gilberto De Nucci, MD Galeno Desenvolvimento de Pesquisas Clinicas Ltda. - ME

Layout table for additonal information
Responsible Party: Biolab Sanus Farmaceutica
ClinicalTrials.gov Identifier: NCT03320486     History of Changes
Other Study ID Numbers: GDN 018/16
First Posted: October 25, 2017    Key Record Dates
Last Update Posted: January 16, 2019
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Biolab Sanus Farmaceutica:
Mycoses
Dermatomycoses
Antifugal Agents
Dapaconazole

Additional relevant MeSH terms:
Layout table for MeSH terms
Tinea
Tinea Pedis
Dermatomycoses
Skin Diseases, Infectious
Infection
Mycoses
Skin Diseases
Foot Dermatoses
Foot Diseases
Pruritus
Skin Manifestations
Signs and Symptoms
Ketoconazole
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP3A Inhibitors